YI CHENG ZHI HUI LTD.
Update：2026/03/31
Industries
Main Industry
Health Care
Main Product/Service
AIxMed’s flagship solution, AIxURO™, is an AI-powered platform for urine cytology. It applies The Paris System for Reporting Urinary Cytology (TPS) to detect and classify atypical and suspicious cells, helping pathologists by offering quantitative risk an
Founded Year
2018
Unified Business No.
50894308
Status
Active
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AIxMed Inc., founded in 2018 and headquartered in Silicon Valley with a presence in Taiwan, is a health‑tech company that combines artificial intelligence with computational cytology. Their mission is to transform cancer diagnosis by applying machine learning and computer vision to cellular imaging, thereby improving diagnostic workflows and patient outcomes.
